Holen Sie sich die Stockscreener-App
3.37
0.88%
-0.03
Handel nachbörslich:
3.39
0.02
+0.59%
Schlusskurs vom Vortag:
$3.40
Offen:
$3.4
24-Stunden-Volumen:
760.43K
Relative Volume:
1.01
Marktkapitalisierung:
$646.02M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-7.6591
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
-2.88%
1M Leistung:
+6.31%
6M Leistung:
+2.12%
1J Leistung:
-10.85%
1-Tages-Spanne:
$3.345
$3.45
1-Wochen-Bereich:
$3.305
$3.54
52-Wochen-Spanne:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.37 | 651.78M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Real time scanner hits for Arbutus Biopharma Corporation explainedWeekly Profit Report & Verified Trade Idea Suggestions - Newser
Understanding Arbutus Biopharma Corporation’s price movementWeekly Trend Report & Safe Capital Growth Plans - Newser
XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation stock outlook for YEARWeekly Growth Portfolio Performance Summary - Newser
Forecasting Arbutus Biopharma Corporation price range with options dataStrong Buy Opportunity with Volume Support - Newser
Is Arbutus Biopharma Corporation stock ready for a breakoutStrategy Playbook for Risk Controlled Trades - Newser
Is Arbutus Biopharma Corporation stock reversal real or fakeBuy/Sell Zone Confirmation Technical Analysis - Newser
News impact scoring models applied to Arbutus Biopharma CorporationMomentum-Based Prediction for Quick Returns - Newser
Arbutus Biopharma Corporation stock momentum explainedTrading Watchlist with Real Time Filters - Newser
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
How to integrate Arbutus Biopharma Corporation into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
What moving averages say about Arbutus Biopharma CorporationFree Smart Money Tracking Signal Generator - Newser
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Position Decreased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Applying big data sentiment scoring on Arbutus Biopharma CorporationTechnical Safety Zone Pattern Recognition - Newser
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Wall Street Zen - Defense World
Is now a turning point for Arbutus Biopharma CorporationFree Alpha Focused Technical Trade Signals - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryFree Community Strategy With High Win Rate - Newser
When is the best time to buy Arbutus Biopharma Corporation stockPortfolio Safety Metrics and Return Analysis - Newser
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug - MyChesCo
What risks could impact Arbutus Biopharma Corporation stock performanceLong Term Stock Growth Plan Suggestions - Newser
Arbutus: Q2 Earnings Snapshot - Connecticut Post
Arbutus Biopharma Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Arbutus Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
Arbutus Biopharma Reports Q2 Earnings of $2.523mln, Revenue of $10.739mln, EPS of $0.01 - AInvest
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 an - GuruFocus
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Real time social sentiment graph for Arbutus Biopharma CorporationHigh Return Strategy with Low Risk - Newser
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma Corporation stock trendline breakdownMarket Timing Strategy with Technical Filters - Newser
What are the latest earnings results for Arbutus Biopharma CorporationBuild a diversified portfolio for steady growth - Jammu Links News
What are the technical indicators suggesting about Arbutus Biopharma CorporationTriple-digit returns - Jammu Links News
What data driven models say about Arbutus Biopharma Corporation’s futureShort Term High Yield Stock Tips for Active Traders - beatles.ru
Bank of New York Mellon Corp Decreases Holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Technical analysis overview for Arbutus Biopharma Corporation stockFree Buy Low Sell High Stock Watch - Newser
Arbutus Biopharma Corporation Recovery Hinges on Volume BreakoutSecure Return Focused Investment Plan Released - metal.it
Published on: 2025-07-30 00:59:28 - Newser
Will breakout in Arbutus Biopharma Corporation lead to full recoveryFree Reliable Chart-Based Trade Entries - Newser
Published on: 2025-07-28 23:59:46 - beatles.ru
What catalysts could drive Arbutus Biopharma Corporation stock higher in 2025Consistently exceptional gains - Jammu Links News
Arbutus Biopharma Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):